Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | PI4KA | P42356 | 1/20 | 0.47 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.47 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 9/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 7/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 6/20 | 0.42 |
| ▸ | CDK1 | P06493 | 5/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.37 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30539287 | 1.00 | ADORA2A (0.47) | ADORA2AADORA1PI4KBADORA2BPI4KA | |
| SCHEMBL5025564 | 0.85 | FDPS (0.41) | ADORA2AADORA1PI4KBADORA2BPI4KA | |
| Tert-Butyl Formate SCHEMBL27997839 | 0.83 | FDPS (0.36) | ADORA2AADORA1PI4KBADORA2BPI4KA | |
| SCHEMBL22571187 | 0.82 | ADORA2A (0.53) | ADORA2AADORA1PI4KBADORA2BPI4KA | |
| SCHEMBL19392006 | 0.81 | FDPS (0.38) | ADORA2AADORA1PI4KBADORA2BPI4KA | |
| SCHEMBL19392060 | 0.81 | FDPS (0.38) | ADORA2AADORA1PI4KBADORA2BPI4KA | |
| SCHEMBL28186936 | 0.81 | FDPS (0.43) | FDPSCDK2CCNA2CCNA1CDK5 | |
| SCHEMBL14993002 | 0.81 | FDPS (0.43) | FDPSHDAC1HDAC6MEN1ALDH1A1 | |
| SCHEMBL27497585 | 0.81 | CCNB2 (0.40) | ADORA2AADORA1PI4KBADORA2BPI4KA | |
| SCHEMBL1831228 | 0.80 | USP5 (0.48) | FDPSCDK2CCNA2CCNA1CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112876474-A | Dimethoxy tetrahydroisoquinoline substituted purine derivative, preparation method thereof and application thereof in antitumor drugs | 林剑雄 | 2021-06-01 | — | — | CN | claimed |
| US-10866241-B2 | Method for the prognosis and treatment of cancer metastasis | INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ES) | 2020-12-15 | — | — | US | claimed |
| US-20260015339-A1 | CALIX[4]ARENES WITH HIGH ANTICANCER ACTIVITY | UNIVERSITE GRENOBLE ALPES (FR) | 2026-01-15 | — | — | US | disclosed |
| EP-4655285-A1 | CALIX[4]ARENES WITH HIGH ANTICANCER ACTIVITY | Université Grenoble Alpes (FR) | 2025-12-03 | — | — | EP | disclosed |
| US-12312642-B2 | Method for the diagnosis, prognosis and treatment of breast cancer metastasis | FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) (ES) | 2025-05-27 | — | — | US | disclosed |
| US-20250115912-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER METASTASIS | FUNDACIO INST DE RECERCA BIOMEDICA IRB BARCELONA (ES) | 2025-04-10 | — | — | US | disclosed |
| US-12196758-B2 | Method for the prognosis and treatment of cancer metastasis | FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) and INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ES) | 2025-01-14 | — | — | US | disclosed |
| WO-2024156819-A1 | CALIX[4]ARENES WITH HIGH ANTICANCER ACTIVITY | UNIVERSITE GRENOBLE ALPES (FR) | 2024-08-02 | — | — | WO | disclosed |
| EP-4406939-A1 | CALIX[4]ARENES WITH HIGH ANTICANCER ACTIVITY | Université Grenoble Alpes (FR) | 2024-07-31 | — | — | EP | disclosed |
| US-20240240182-A1 | HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-07-18 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2000044750-A1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND Iλ-A$g(a) | CV THERAPEUTICS, INC. (US) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000043394-A1 | SUBSTITUTED NITROGEN HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL USE THEREOF | ÚSTAV EXPERIMENTÁLNÍ BOTANIKY AV CR (CZ) | 2000-07-27 | — | — | WO | disclosed |
| EP-1021186-A4 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkappaB-alpha | CV THERAPEUTICS INC (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-1021186-A1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkappaB-alpha | CV THERAPEUTICS, INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-2000033657-A1 | METHOD TO IDENTIFY REGULATORS OF CDK ACTIVITY | CROPDESIGN N.V. (BE) | 2000-06-15 | — | — | WO | disclosed |
| CN-1231611-A | Puring inhibitors of cylin dependent kinase 2 and I'kappa'beta-'alpha' | CV THERAPEUTIC INC (US) | 1999-10-13 | — | — | CN | disclosed |
| US-5866702-A | Purine inhibitors of cyclin dependent kinase 2 | CV THERAPEUTICS, INCORPORATION (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1998005335-A9 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IλB-$g(a) | — | 1998-05-28 | — | — | WO | disclosed |
| WO-1998005335-A1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IλB-$g(a) | CV THERAPEUTICS, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015339-A1 | CALIX[4]ARENES WITH HIGH ANTICANCER ACTIVITY | CBR1, CYP4X1, CBR3 | ADORA2A 2242/4885ADORA1 1017/4885PI4KB 2091/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | ADORA2A 3249/4885ADORA1 3200/4885PI4KB 228/4885 |
| US-12196758-B2 | Method for the prognosis and treatment of cancer metastasis | MAFG, BRCA1, BCOR | ADORA2A 2188/4885ADORA1 1380/4885PI4KB 3218/4885 |
| US-20250115912-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER METASTASIS | MAFG, RHOXF2, MAFK | ADORA2A 4661/4885ADORA1 4785/4885PI4KB 3736/4885 |
| US-10866241-B2 | Method for the prognosis and treatment of cancer metastasis | MAFG, BRCA1, BCOR | ADORA2A 2188/4885ADORA1 1380/4885PI4KB 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.